Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOOKS like an easy 50%+ up gap to fill. Even with a little dilution.
1.30. Reasonable. Eom
No doubt!! Probably triggered A LOT of stop losses.
Message in reply to:
50% discount in one day is a big flush out, float is still low even with the effect filing, cure the opioid epidemic, make millions, that simple, hoping for that
I started playing post RS volatility a while ago. CERTAINLY has its risk/reward factor.
Cheers.
ENSC pre market dip. I took a few bites under 1.10. & 1.12.
Doesn't take much to wiggle a low floater.
Discount. S-1 notice of effect posted. Looks like they'll dilute right into another RS.
Gotta love the volatility of these bios after the RS's though.
CFRX .147 check out the weekly. Took the dip under the $2 SCYX. 1.90. See how that works out for the swing.
Didn't even check their filings. Thanks! That's quite the dilution for sure.
Watching the chart thinking it may be back in its channel and worth a quick swing.
SOBR
Added a "follow" mark.
SOBR looks to be nearing the $ again. Why?? Who knows!
SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis
https://finance.yahoo.com/news/scynexis-announces-fda-approval-second-130000442.html
Thinking this puppy plays well into next summer.
Now I wait for the chart. Or I should say, "my chart" set up. But I made my plan. Small bite 1st.
This could still see under the $ but I took a nibble here. 1.03.
They get news follow up with Janssen and this could see quite the momentum.
Dear Stockholder:
We are pleased to invite you to attend the Special Meeting of stockholders (the “Special Meeting”) of Hepion Pharmaceuticals, Inc. (“Hepion” or the “Company”), which will be held on December 15, 2022 at 9:00 a.m. local time at our offices, located at 399 Thornall Street, First Floor, Edison, NJ 08837, for the following purposes:
1. To grant discretionary authority to our board of directors to (i) amend our certificate of incorporation to combine outstanding shares of our common stock into a lesser number of outstanding shares, or a “reverse stock split,” at a specific ratio within a range of one-for-two (1-for-2) to a maximum of a one-for-twenty (1-for-20) split, with the exact ratio to be determined by our board of directors in its sole discretion; and (ii) effect the reverse stock split, if at all, within one year of the date the proposal is approved by stockholders; and
2. To transact such other matters as may properly come before the Special Meeting and any adjournment or postponement thereof.
Our board of directors has fixed the close of business on November 8, 2022 as the record date for a determination of stockholders entitled to notice of, and to vote at, the Special Meeting or any adjournment or postponement thereof.
https://ih.advfn.com/stock-market/NASDAQ/hepion-pharmaceuticals-HEPA/stock-news/89607816/proxy-statement-definitive-def-14a
How is this going to work for US shareholders holding ALRTF shares thru Nevada?
The Ordinary Shares have been approved for quotation on the OTCQB tier of the OTC Markets Group under the trading symbol “ALRTF”.
In consequence of the Redomicile Merger, ALR Nevada expects to file a Form 15 with the SEC to terminate the registration of the Common Stock under the Exchange Act and to suspend its reporting obligations with respect to the Common Stock under the Exchange Act.
SCYNEXIS, Inc.Novel Anti-Infective Treatments
https://www.scynexis.com/pipeline
https://www.scynexis.com/?_sc_token=v2%253ArCFB5M7kDhF0DendplAumDfp0mLJQmmPjXibbF655Pwpp8L8St9zJ5JWXuLRyKtUtDU3NLAry760CeTu07jPC2-7zJNvjIcdmALhP5-txfDhpy-ro8W8Uv93cVU_P05u-1Nm3Y4zfahqmFmswTq5LuZmc2e1aC9Ss1Nnefn-7ep8OcQJeNtAIyo0DvbfqJpL
https://finviz.com/quote.ashx?t=SCYX&p=d
Price history...
https://www.dividendinvestor.com/dividend-news/?symbol=scyx
Looking better than I thought. See how this puppy plays into 1st half 2023.
Lol. Out 2.19. Paid for dinner.
Pushing on up!
TOVX (aka SYN) .712 Still on my list for playing the technical side.
TOVX pincher
So am I wrong that this is now a one hit wonder that has about 6 months to live? Maybe LifeSci sees the writing on the wall. I never cared much for them myself. My take has been they provide funding and short their own companies like any other hedge fund betting on the typical bio to fail.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1053691/000143774922027266/dffn20220930_10q.htm
https://finviz.com/quote.ashx?t=DFFN&p=d
Their next study initiates 1st Q 2023, IF they can make it happen.
Do your DD. I haven't looked at this one since before their RS.
MYNZ $9.50 PM 9.50/10.08
$9.50$0.58(6.50%)
Bid9.50Ask10.08
Vol2.5KLight
Message in reply to:
MYNZ $8.43 sneaky low volume heading for the power zone.
Just saw this is having a proxy battle. See what shakes out.
https://finance.yahoo.com/news/lifesci-special-opportunities-responds-recent-222000344.html
https://finance.yahoo.com/news/diffusion-pharmaceuticals-sees-significant-progress-113000901.html
MYNZ $8.43 sneaky low volume heading for the power zone.
"We expect to submit our new drug application (NDA) application to the FDA for HyBryte(TM) during this quarter. Additionally, we are continuing our expansion into new disease indications with synthetic hypericin having received FDA investigational new drug (IND) clearance for a Phase 2a clinical trial in mild-to-moderate psoriasis, also expected to begin before year end.
https://finance.yahoo.com/news/soligenix-inc-showcase-2022-milestones-120000272.html
Stopped out at .16. Wasn't watching close enough.
TENX
Starter .165 TENX. I think she pushes to the .20's before close. S/L .145.
I like SIEN into the low .40's. Go from there. Good eye Mark.
Stuck to the $1.10. Nice. And JUST maybe with the reorg they've done we'll see the follow thru.
Athersys, Inc. Announces Closing of $5.5 Million Confidentially Marketed Public Offering
.
Source: Business Wire
Athersys, Inc. (Nasdaq: ATHX) today announced the closing of its previously announced confidentially marketed public offering with healthcare-focused U.S. institutional investors for the purchase of 5,004,545 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 10,009,090 of common stock at a combined purchase price of $1.10, resulting in gross proceeds of approximately $5.5 million before deducting placement agent fees and other offering expenses. The warrants have an exercise price of $1.10 per share, are exercisable immediately following the date of issuance and will expire five years from the date of issuance.
The Company intends to use the net proceeds from the offering for general corporate purposes.
A.G.P./Alliance Global Partners acted as sole placement agent for the offering.
This offering of the common stock, common stock equivalents and warrants is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-235945) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). A final prospectus supplement describing the terms of the proposed offering has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Athersys
Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, inflammatory and immune and other critical care indications and has two ongoing clinical trials evaluating this potential regenerative medicine product. Investors and others should note that we may post information about the Company on our website at www.athersys.com and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms. It is possible that the postings could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in the Company to review the information we post on our website at www.athersys.com and on our social media accounts. Follow Athersys on Twitter at www.twitter.com/athersys. Information that we may post about the Company on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. You should not place undue reliance on forward-looking statements contained on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
?
View source version on businesswire.com: https://www.businesswire.com/news/home/20221110006074/en/
Athersys
Ellen Gurley
Manager of Corporate Communications and Investor Relations
ir@athersys.com
LHA Investor Relations
Tirth T. Patel
212-201-6614
tpatel@lhai.com
I didn't even blink on the dip yesterday for LXRX. This has been a great rinse and repeat player.
Activity Quantity CUSIP
Number Price Principal
Amount Misc
Fees Reg
Fee
YOU BOUGHT XXXX 1.96 XXX.XX 0.00
As of
Trade Date Trade
Date Settlement
Date Interest Commission/Fee Net
Amount
11/09/2022 11/14/2022 0.00 XXX.XX
Took the dip on ATHX yesterday too. A little early but got my average down to around .61. Now they just need to survive and make a deal.
Squeeze this puppy already!!
Chart showing some strength. Closes over 2.20 and the bulls will be in the lead for next week imo.
LXRX daily
Maybe they found a solid buyer for the offering.
https://finance.yahoo.com/news/athersys-reschedules-third-quarter-conference-135500220.html
ATHX
-56.45%
Thu, November 10, 2022 at 5:55 AM·2 min read
In this article:
ATHX
-56.45%
CLEVELAND, November 10, 2022--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it intends to file its quarterly report on Form 10-Q for the three months ended September 30, 2022 with the U.S. Securities and Exchange Commission (SEC) after market close on Monday, November 14, 2022, issue a news release reporting those financial results and recent business highlights before market open on Tuesday, November 15, 2022, and hold a conference call at 11:00 a.m. Eastern Time on Tuesday, November 15, 2022.
The company is rescheduling the reporting of its third quarter 2022 financial results in order to provide sufficient time to complete the Form 10-Q specifically regarding the accounting for recently issued equity warrants.
Details of the rescheduled conference call are as follows:
Date
November 15, 2022
Time
11:00 a.m. (Eastern Time)
Live webcast registration
Webcast link
Phone registration
Call registration link
Shareholders are encouraged to register and listen to the call using the webcast link above. Once registered, you will receive an email containing the toll-free number, a direct entry passcode and a registrant ID. Please send questions you would like management to address in advance of the call to IR@athersys.com. If you have already registered for this call, your registration will automatically roll over to the new date and time.
Get just 1 thing right!! Kaboom! Fry shorty! MOASS!!! Mother of all short squeeze, MOASS lol usually see this on pinks.
This bio needs to get something right. That simple.
Yup, it cracked again. My 1 minute is watching the money flow, momentum, fast sto, OBV and RSI. Want to see the MFI bottom then I'll add or wait.
I think this should recover a bit into the close or in the AM. This offering was clearly seen as desperation, almost similar to $CLVS's release this morning. But only time will tell.
Day's High
0.759
Day's Low
0.53
Sideways. We'll see soon. ATHX .5756.
ATHX av around .65 now. One more around .55 and i'll be happy.
MAYBE!!!! 1.10 offering, you know the MM's chased EVERY SINGLE stop loss there was!!!
Oh yeah, not to mention the float is under 12M.
I just added this to my watchlist. Need to dd. eom
Just saw that. I was looking into CLVS yesterday and this morning. Wondering now if this is playing on the other one you posted on. ATH*. It almost would make sense as far as desperation goes in this sector. Shorts making out like bandits.
GL
Yeah, squeezing down. Taking nibbles though.
Day's High
0.759
Day's Low
0.5926